Precision Cancer Therapies Market Report 2020: Top Companies, Regions, Driving Force and Forecast 2026 – The Market Feed

The Precision Cancer Therapies Market grew in 2019, as compared to 2018, according to our report, Precision Cancer Therapies Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Precision Cancer Therapies Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Precision Cancer Therapies Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-precision-cancer-therapies-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Precision Cancer Therapies Market is analysed based on product types, major applications and key players

Key product type: Hormone Therapy Immunotherapies Targeted Therapy Monoclonal Antibody Therapy Gene Therapy

Key applications: Hospitals Diagnostic Centers Oncology Clinics Research Institutes

Key players or companies covered are: Abbott Laboratories Bayer HealthCare GlaxoSmithKline OncoGenex Pharmaceuticals Hospira Boehringer Ingelheim AstraZeneca Aveo Pharmaceuticals

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-precision-cancer-therapies-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report: 1. What is the current size of the Precision Cancer Therapies Market, at a global, regional & country level? 2. How is the market segmented, who are the key end user segments? 3. What are the key drivers, challenges & trends that is likely to impact businesses in the Precision Cancer Therapies Market? 4. What is the likely market forecast & how will be Precision Cancer Therapies Market impacted? 5. What is the competitive landscape, who are the key players? 6. What are some of the recent M&A, PE / VC deals that have happened in the Precision Cancer Therapies Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us: i2iResearch info to intelligence Locational Office: *India, *United States, *Germany Email: [emailprotected] Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

See the rest here:
Precision Cancer Therapies Market Report 2020: Top Companies, Regions, Driving Force and Forecast 2026 - The Market Feed

Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) – Cheshire Media

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hemophilia Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hemophilia Treatment Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hemophilia Treatment market during the forecast period (2020-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Hemophilia Treatment Market Industry / Sector Trends

Hemophilia Treatment Market size was valued USD 10.5 billion in 2018 and is expected to witness 5.0% CAGR from 2019 to 2025.

U.S. hemophilia treatment market, by disease, 2018 & 2025 (USD Million)

Growing prevalence of hemophilia across the globe will be one of the major market augmenting factors over the forthcoming years. As per the recent statistics published by Centers for Disease Control and Prevention (CDC), hemophilia A affects around 1 in 5,000 live male births in the U.S. Majority of the people with hemophilia are diagnosed at a young age. According to the CDC data, average age of hemophilia diagnosis in the U.S. is 36 months for mild hemophilia, 8 months for moderate hemophilia and 1 month for severe hemophilia. Hence, rise in number of people suffering from hemophilia will enhance the hemophilia treatment market growth in the near future.

Rise in several government initiatives will augment the industry growth over the projection period. Organization including the World Hemophilia Organization along with governments of several countries carry out awareness and diagnosis programs. Government efforts to enhance public health and treat underprivileged people will result in boosting the hemophilia treatment market growth in the near future.

However, high cost of hemophilia medications will be one the major growth impeding factors. High investment, R&D, manufacturing and marketing of drugs by manufacturers is the reason for high cost of the products. High cost of products are unaffordable for the middle and lower income class families, thus resulting in restraining the business growth.

Market Segmentation, Outlook & Regional Insights: Hemophilia Treatment Market

Hemophilia Treatment Market, By Disease

Germany hemophilia treatment market share, by disease, 2018

Hemophilia A treatment market was valued at USD 6,743.7 million in the year 2018. Hemophilia A is a common blood disorder and the prevalence rate is high in developing and underdeveloped regions. As per the recent statistics, around 19,000 people in India suffer from hemophilia and only 15% of the patients are registered. Increase in number of people suffering from hemophilia A and rise in awareness among the people regarding the treatment and medications of hemophilia will result in rise in demand and adoption rate of hemophilia drugs, fueling the business growth.

Hemophilia B treatment market is estimated to grow at 4.0% over the estimation period. As per a recent research article, the prevalence of hemophilia B is quite rare as compared to hemophilia A and the incidence of hemophilia B is around 1 in 30,000 in the U.S. Recent technological advancements has led to growing medications for hemophilia B treatment, hence resulting in boosting the segmental growth.

Hemophilia Treatment Market, By Product

Recombinant factor concentrates market was valued at USD 6,626.9 million in the year 2018. Rise in production of recombinant factor concentrates has provided growth opportunity to treat hemophilia and overcome limited availability of plasma-derived concentrates. Also, increased safety of replacement therapy with the help of recombinant factor concentrates has dramatically enhanced the quality of patient life. Increase in preference of recombinant factor concentrates in treatment of hemophilia will ultimately lead to augmenting the business growth over the forecast period.

Extended half-life products market is estimated to witness a robust growth of 5.3% over the forecast period. Recent research and development has led to the production of new factor concentrates that are efficient and need less frequent injections. The reason for fewer injections are due to the increased half-life of the product. Hence, recent technological advancements and new product launches will lead to increase in demand and adoption rate of extended half-life products, thereby fueling the business growth.

Hemophilia Treatment Market, By Patient

Hemophilia treatment in adults was valued at USD 6,778.1 million in the year 2018. As per a recent research article, around 65% of the people suffering from hemophilia are adults. In some of the adults mild hemophilia is diagnosed in the later stages of life. As the age of patients increases, the need for hemophilia care also increases. There are various possibilities of developing moderate to severe hemophilia in adults. Hence, growing age results in rise in chances of developing hemophilia in adults, thereby boosting the demand for hemophilia treatment in the near future.

Hemophilia treatment in pediatrics is projected to grow at 5.2% over the estimation period. Hemophilia is inherited diseases that are passed to children from gene located on X-chromosome. In approximately one third of children, no family history of hemophilia is found, and the disease occurs due to gene mutation. Children with hemophilia gene bruise easily, bleed more with surgeries and have frequent nose bleedings. According to the National Center for Biotechnology Information, severe form of factor deficiencies including hepatitis A and hepatitis B were diagnosed in the neonates with 52% and 68% of cases respectively. Hence, increase in prevalence of hemophilia in children will augment the hemophilia treatment market growth in the near future.

Hemophilia Treatment Market, By Treatment

Prophylaxis treatment market was valued at USD 7,219.9 million in the year 2018. Long-term prophylaxis treatment is considered as standard of care to prevent chronic arthropathy and joint bleeding in patients with severe hemophilia. As per a recent research, it was observed that the prophylaxis treatment for hemophilia was quite effective and slowed the progression of joint damage. Majority of patients and healthcare providers opt for prophylaxis treatment owing to its efficiency and better end results. Hence, increase in preference of prophylaxis treatment will further augment the business growth in the near future.

On demand treatment market is estimated to grow at 5.2% over the forthcoming years. People suffering from mild to moderate hemophilia are treated with on demand treatment to prevent bleeding. Children with severe hemophilia initially receive prophylactic therapy to prevent bleeding; however, after reaching adulthood, they switch to on-demand treatment for several reasons, such as strict work schedules, inconvenience of visiting doctors or going to a clinic several times a week, along with high expenditure related to continuous prophylactic therapy. Hence, the aforementioned reasons will be responsible for the market growth of on demand treatment segment.

Hemophilia Treatment Market, By Therapy

Factor replacement therapy market was valued at USD 9,574.2 million in the year 2018. As per the Medical and Scientific Advisory Council (MASAC) of National Hemophilia Foundation (NHF), the use of recombinant factor concentrates in children is quite effective as the recombinant factor does not contain actual human blood and cannot transmit harmful viruses including hepatitis. Hence, the use of factor replacement therapy is quite common due to direct infusion of clotting factors, resulting in boosting the segmental growth.

Non-factor replacement therapy is projected to show rapid growth of 38.3% over the estimation period. One of the challenging problems in the treatment of hemophilia is the development of alloantibodies against the infused factor concentrates. Development of inhibitors render the factor replacement therapy ineffective, leading to high risk of morbidity and mortality in patients. Also, there is growing interest in non-factor replacement therapy agents that act by inhibiting anticoagulant pathways or enhancing coagulation. Hence, introduction of new therapeutic agents in hemophilia treatment will enhance the business growth.

Hemophilia Treatment Market, By Drug Class

Coagulation factors market was valued at USD 9,948.3 million in the year 2018. Hemophilia is considered as hereditary blood disease with coagulation time. The use of coagulation factors is quite common and is used mostly in the replacement therapy. Absence or improper functioning of several clotting factors in the blood such as factors VIII, XI, etc. result in causing hemophilia. Hence, use of several clotting factors to replace the absent blood clotting factors will lead to boosting the hemophilia treatment market growth.

Vasopressin drug class market is estimated to grow at 6.0% in the near future. Patients suffering from mild hemophilia use vasopressin drugs for joint and muscle bleeds, bleeding in mucous membranes of nose and mouth and pre and post-surgery. Vasopressin drugs comes in injectable and nasal spray form and is comparatively easy to use. Hence, the aforementioned factors will be responsible for the market growth of vasopressin drug class.

Hemophilia Treatment Market, By Route of Administration

Injectable route of administration for hemophilia treatment was valued at USD 9,629.3 million in the year 2018. Majority of the drugs and factor concentrate products are intravenously given to patients for better and quick results. Intravenous route of administration helps the medications to directly interact with the blood. Hence, majority of healthcare providers opt for injectable or intravenous route of drug administration to treat hemophilia for better and quick results, hence boosting the market growth.

Nasal spray or intra nasal route of administration will grow at 6.0% over the forecast period. Drugs including vasopressin are required to be taken by patients for joint and muscle bleeds, and bleeding in mucous membranes of nose and mouth. Several advantages offered by nasal spray such as ease of use and user convenience will result in growing demand, thereby fueling the business growth.

Hemophilia Treatment Market, By End-use

Hemophilia treatment centers as end-use was valued at USD 4,134.6 million in the year 2018. A substantial proportion of hemophilia treatment is carried out in such centers. During the forecast period, the hemophilia treatment center end-use market segment will continue to lead, owing to rising number of special care provided and peoples increased preference for these centers over other healthcare settings.

Clinics as end-use is estimated to grow at 5.3% in the near future. Clinics provide fast-track treatment and infusion of factor concentrates to patients. Also, immediate and short-time treatment provided during the daytime to people with busy and hectic work schedule will enhance business growth in the near future.

Hemophilia treatment Market, By Region

Europe hemophilia treatment market, by country, 2025 (USD Million)

U.S. dominated the North America hemophilia treatment market and was valued at USD 3,539.3 million in the year 2018. As per the Hemophilia Federation of America, hemophilia A affects around 1 in 5,000 people in the U.S. and approximately 400 new-borns are diagnosed with hemophilia every year. Also, presence of favorable reimbursement and insurance in the country will result in growing demand and adoption rate of hemophilia medications, expanding the hemophilia treatment market growth in the country.

India hemophilia treatment market is projected to grow at 9.2% over the estimation period. Various government initiatives has helped in building necessary infrastructure, empower healthcare providers and patients to self-administer treatment at home, hence helping patients achieve a better quality of life. Recent technological advancements, rise in awareness among people, new product launches and government initiatives will augment the business growth over the forecast period.

Key Players, Recent Developments & Sector Viewpoints: Hemophilia Treatment Market

Major industry players involved in the hemophilia treatment market include Swedish Orphan Biovitrum AB, Sanofi SA, Pfizer, Novo Nordisk, Genentech, CSL Behring, Biogen, among other market players. These players have implemented several strategic initiatives such as collaborations, merger and acquisitions, new product launches and partnerships that have enhanced their financial stability, helped them evolve as major industrial players and gain strong market position.

Hemophilia Treatment Industry Viewpoint

Hemophilia has been an extremely old and critical disease that the global population has been facing. People in ancient times have written and articulated about bleeding problems. Some of the bleeding problems identified have been different as compared to others. But little they knew about blood clots and the disease caused by their deficiency. Until before World War II, doctors learned about hemophilia A and its cause due to deficiency of factor VIII. Several other blood factors were recognized later on and Roman numeral names were given to avoid confusion. Hemophilia research has come a long way with scientists discovering human blood in different groups, hence helping blood transfusions to be more successful. In 1960s, Dr. Judith Pool discovered a procedure to freeze and thaw plasma to get a layer of factor-rich plasma called as cryoprecipitate. Use of cryoprecipitate was the best way of stopping hemophilia bleeding. Later on, the greatest breakthrough that came in hemophilia treatment was the development and introduction of factor concentrates. These clotting factors can be freeze-dried to a powder that can be easily stored and consumed. With the help of these factor concentrates, people suffering from hemophilia can be treated quickly with maximum efficiency. Also, factor concentrates have helped people treat their bleedings at home or at work, resulting in people to lead normal lives. Also, development and introduction of new medications and technologies such as non-factor replacement therapy, extended half-life products, gene therapy, etc. will augment the growth of hemophilia treatment market growth in the near future.

Key Insights Covered: Exhaustive Hemophilia Treatment Market

1. Market size (sales, revenue and growth rate) of Hemophilia Treatment industry.

2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Hemophilia Treatment industry.

3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Hemophilia Treatment industry.

4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Hemophilia Treatment industry.

Research Methodology: Hemophilia Treatment Market

Looking for more? Check out our repository for all available reports on Hemophilia Treatment in related sectors.

Quick Read Table of Contents of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Read more:
Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media

Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine – Newswise

Newswise DALLAS Dec. 3, 2020 A team led by UT Southwestern has derived a new intermediate embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing nave embryonic stem cells (those about four days post-fertilization in mice) and primed epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, theres been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named XPSCs from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

These XPSCs have enormous potential. Our study helps open the door to each of these possibilities, says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep nave PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for nave PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF- pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-.

Aiming for the preferred environment for XPSC derivation, Wu and his colleagues placed cells from early mouse embryos into cultures containing chemicals and growth factors that activate all three pathways. These lab-grown cells were extremely stable in culture and able to multiply without developing any further for approximately two years.

Additional experiments showed that these cells met the expectations researchers have long strived to meet of contributing to chimeras and directly differentiating into primordial germ cells. Wu and his colleagues made intraspecies chimeras of mice using cells derived from mice with different coat colors by injecting the cells into early mouse embryos. They also tracked the contributions of the XPSCs by tagging the cells with a fluorescent protein and then identifying them throughout the resulting offsprings body.

Wus team made interspecies chimeras by injecting horse XPSCs into early mouse embryos and allowing the embryos to develop in mice for several days. Surprisingly, although horses have a comparatively long gestational period nearly a year the researchers found that these foreign cells had contributed to mouse organ development, indicating that signals from the mouse cells determine organ developmental timelines.

Like XPSCs from other species, the human cells showed that they were capable of differentiating into a variety of tissues if culture conditions allowed them to progress in development, as well as directly form primordial germ cells in a dish.

Other UTSW researchers who contributed to this study include Leqian Yu, Yulei Wei, Carlos A. Pinzon Arteaga, Masahiro Sakurai, Daniel A. Schmitz, Canbin Zheng, and Emily D. Ballard. Yu and Wu are inventors on a patent application arising from this work.

This study was funded by the Cancer Prevention and Research Institute of Texas (CPRIT No. RR170076), the Hamon Center for Regenerative Science and Medicine, the Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011), and the Asahi Glass Foundation.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 23 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

The rest is here:
Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine - Newswise

UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies – UCLA Newsroom

UCLA Health

The new 13,000-square-foot facility will be located in UCLAs Center for the Health Sciences.

UCLA has received a $7.3 million grant from the National Institutes of Health to build a state-of-the-art facility in which to produce gene and cell therapies aimed at treating a host of illnesses and conditions.

The new 13,000-square-foot facility, to be constructed in UCLAs Center for the Health Sciences, will provide a highly regulated environment with features such as systems to manage air flow and filtering, laboratory spaces and bioreactors. The new facility is expected to be ready for use in 2023.

This grant provides critical funds to build a facility that will enable the development of a new generation of cellular therapies for cancer and other deadly diseases, said Dr. AntoniRibas, a UCLA professor of medicine and director of the Parker Institute for Cancer Immunotherapy Center at UCLA.

The new facility will be built according to U.S. Food and Drug Administrationgood manufacturing practices, a set of guidelines intended to ensure that facilities producing products for human use are built to maximize safety and effectiveness, and to reduce the risk for contamination.

It will replace a facility in UCLAs Factor Building that UCLA scientists currently use for similar research. But that space, which was put together by combining existing research laboratories, lacks the capacity to process certain cells and handle other bioengineered products, and it cannot accommodate the growing number of UCLA scientists pursuing research on gene and cell therapies, said Dr. Stephen Smale, vice dean for research at the David Geffen School of Medicine at UCLA and principal investigator of the NIH grant.

The new facility will be larger, so it will be able to support more projects simultaneously, and its design will allow a smooth flow of products into and out of the facility, Smale said. The larger number of rooms is really important because even when a single therapy is being tested, cells from each patient need to be processed in their own room.

Dr. Eric Esrailian, chief of theUCLA Vatche and Tamar Manoukian Division of Digestive Diseases, is helping to lead the expansion of UCLAs immunology and immunotherapy efforts. It will be a cornerstone for UCLAs commitments to building on existing strengths in the areas of immunology and immunotherapy and expanding toward the creation of a transformational institute in these fields, he said.

Despite the shortcomings of the current space, UCLA researchers have still produced groundbreaking work in it. These include tumor-targeting therapies developed by Ribas, Dr. Donald Kohn, Dr. Linda Liau, and other UCLA researchers.

Ribas, Kohn and Liau are also members of theUCLA Jonsson Comprehensive Cancer Centerand theUCLA Broad Stem Cell Research Center. Kohn is a distinguished professor of microbiology, immunology and molecular genetics and Liau is chair of UCLAs department of neurosurgery.

Kohn, who alsodeveloped a cure for bubble baby syndrome,said he will welcome the new facility because of its increased capacity for researchers to pursue treatments and cures that could significantly improve the health and quality of life of so many people. For instance, it will have the capacity to produce large batches of viral vectors microbes that make it possible to introduce potentially curative genes into cells for gene therapy studies.

This new facility will allow the innovative cell and gene therapies pioneered at UCLA to be available to a wider number of patients and accelerate the development of novel cures, said Kohn, whose work has also led to an experimental stem cell gene therapy for sickle cell disease that is showing promising early results in clinical trials.

Liau, a neuro-oncologist, said the new facility will enable researchers to create personalized vaccines and cell therapies for a much larger number of patients.

In the current facility, we are only able to enroll one patient at a time in our cell therapy trials, so many eligible patients have had to be turned away, Liau said.With greater capacity to manufacture gene and cell therapy products that meet FDA good manufacturing practice standards, this new UCLA facility will really allow us to further innovate and accelerate our translational research toward a cure for brain cancer.

See more here:
UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom

Possible Role for Comprehensive Molecular ProfilingBased Treatment Selection in Newly Diagnosed AML, Study Suggests – Cancer Therapy Advisor

The feasibility of a precision medicinebased approach was demonstrated for patients with newly diagnosed acute myeloid leukemia (AML), according to findings from a phase 1/2 clinical trial reported in Nature Medicine.

The current standard of care for the treatment of patients diagnosed with AML involves prompt initiation of intensive induction chemotherapy, such as 7 days of standard-dose cytarabine and 3 days of daunorubicin, or administration of a hypomethylating agent for those deemed unable to tolerate standard induction therapy, to prevent rapid progression of disease in this predominantly older patient population.

Hence, time for comprehensive molecular characterization of the disease is not built into typical treatment protocols for patients with newly diagnosed AML. However, long-term outcomes of patients with newly diagnosed AML treated with intensive chemotherapy without autologous hematopoietic stem cell transplantation have been shown to be poor, and hypomethylating agents are not a curative approach in the setting of AML.

This nonrandomized, open-label, multicenter, umbrella protocol study sponsored by the Leukemia & Lymphoma Society (BEAT AML Master Trial; ClinicalTrials.gov Identifier: NCT03013998) enrolled adult patients with suspected AML prior to the administration of frontline treatment.

During a 7-day period prior to treatment assignment, bone marrow biopsy specimens of eligible patients were subjected to cytogenetic analysis, comprehensive molecular profiling using next-generation sequencing, and a FLT3-ITD ratio testing. On the basis of these results, patients with a dominant AML clone characterized by an actionable alteration were assigned to 1 of multiple molecularly defined substudy treatment arms, whereas those without evidence of such an alteration were assigned to the marker-negative subgroup.

In describing the purpose of this study, the investigators stated that they collaboratively implemented a new prospective clinical trial approach aimed at facilitating frontline treatment assignments to specific genomic-defined AML subtypes.

Of the 395 eligible patients, approximately 95% were assigned to treatment within 7 days of bone marrow biopsy collection. Of note, only 26 of these patients exhibited evidence of rapid disease progression necessitating initiation of therapy during the 7-day testing window.

The most common mutational drivers identified were DNMT3A (22.7%), TET2 (19.6%), TP53 (19.1%), ASXL1 (19.1%) and SRSF2 (18.4%).

Regarding molecularly based treatment assignment, the study authors commented that these data show that there were few co-occurring dominant mutations that could have been used for an alternative therapeutic assignment.

Only 224 (56.7%) of patients agreed to receive treatment according to their assigned BEAT AML substudy treatment arm, with 103, 28, and 38 patients selecting standard-of-care treatment, alternative investigational therapy, and palliative care, respectively.

Patients were encouraged to select an alternative therapy (alternative investigational therapy, [standard of care] or palliative care) if the patient with their health-care providers deemed this a better option, the study investigators noted.

A key finding from this study was the 30-day mortality of patients starting at initial study enrollment was 3.7% for patients enrolled on the BEAT AML trial protocol and 20.4% for those who choose to receive standard-of-care therapy.

Furthermore, rates of 1-year overall survival were 54.7%, 27.6%, 11%, and 57.4% for patients treated on the BEAT AML protocol, or with standard-of-care therapy, palliative care, and alternative investigational therapy, respectively.

However, the study investigators noted that while our study demonstrates the feasibility of precise molecular treatment assignment in older adults with AML, it does not clearly differentiate the benefit of treatment assignment based on a molecular target from better outcome that occurs simply from enrolling on a clinical trial.

They also emphasized that this approach requires a detailed team-coordinated effort by investigators, patients and caregivers, genomic laboratories, cytogenetic laboratories and a central treatment assignment team.

In their concluding remarks, the researchers commented that randomization of specific large genomic groups to targeted therapy versus [standard of care] or, in less common genomic groups, comparison of treatment with targeted therapy to either real-world data or synthetic controls, will be required to determine the comparative effectiveness of a precision medicine-based approach vs standard-of-care therapy in patients with newly diagnosed AML.

Reference

Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. Published online October 26, 2020. doi:10.1038/s41591-020-1089-8

Read more from the original source:
Possible Role for Comprehensive Molecular ProfilingBased Treatment Selection in Newly Diagnosed AML, Study Suggests - Cancer Therapy Advisor

Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc – The…

A new report added by Big Market Research claims that the globalHuman Embryonic Stem Cells marketgrowth is set to reach newer heights during the forecast period,2020-2026.

This report is meticulous research formulated by market professionals by deeply analyzing key driving and restraining factors, major regional market situations, major players, and size & scope of the market. The report also offers value chain analysis, Porters Five Forces model, and PEST analysis. Furthermore, the competitive landscape in different regions is elucidated in the report to assist top market players, new entrants, and investors determine investment opportunities.

Request for a sample copy of this report @https://www.bigmarketresearch.com/request-sample/3848332?utm_source=SHASHI&utm_medium=MC

The report also explains the factors boosting the market growth. The major drivers of the Human Embryonic Stem Cells market are:

Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc., Biotime, Inc. / Cell Cure Neurosciences LTD, Thermo Fisher Scientific, Inc., CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza Group AG, Kite Pharma, Cynata Therapeutics Ltd. ,

In addition, the research report provides a comprehensive analysis of the key segments of the Human Embryonic Stem Cells market. An outline of each market segment such as type, application, and region are also provided in the report.

By Application: Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing

On the basis of region, the market is evaluated across:

North America (U.S., Canada, Mexico, etc.)

Asia-Pacific (China, Japan, India, Korea, Australia, Indonesia, Taiwan, Thailand, etc.)

Europe (Germany, UK, France, Italy, Russia, Spain, etc.)

Middle East & Africa (Turkey, Saudi Arabia, Iran, Egypt, Nigeria, UAE, Israel, South Africa, etc.)

South America (Brazil, Argentina, Colombia, Chile, Venezuela, Peru, etc.)

The report outlines company profiles, product specifications and capacity, production value, and 2020-2026 market shares of key players active in the market. Moreover, the research presents the performance and recent developments of the foremost players functioning in the market. The insights delivered in the report are valuable for individuals or companies interested in investing in the Human Embryonic Stem Cells industry. These insights might help market players in devising effective business strategies and taking the required steps to obtain a leadership position in the industry.

Shareholders, stakeholders, product managers, marketing officials, investors, and other professionals in search of detailed data on supply, demand, and future predictions of the Human Embryonic Stem Cells market would find the report beneficial. Furthermore, we endeavor to deliver a customized report to fulfill the special requirements of our clients, on-demand.

Research Objective

To analyze and forecast the market size of global Human Embryonic Stem Cells market.

To classify and forecast global Human Embryonic Stem Cells market based on product, sources, application.

To identify drivers and challenges for global Human Embryonic Stem Cells market.

To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in global Human Embryonic Stem Cells market.

To conduct pricing analysis for global Human Embryonic Stem Cells market.

To identify and analyze the profile of leading players operating in global Human Embryonic Stem Cells market.

The report is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities. Key target audience are:

Manufacturers of Human Embryonic Stem Cells

Raw material suppliers

Market research and consulting firms

Government bodies such as regulating authorities and policy makers

Organizations, forums and alliances related to Human Embryonic Stem Cells

Highlights following key factors:

:- Business description A detailed description of the companys operations and business divisions. :- Corporate strategy Analysts summarization of the companys business strategy. :- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats. :- Company history Progression of key events associated with the company. :- Major products and services A list of major products, services and brands of the company. :- Key competitors A list of key competitors to the company. :- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company. :- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Avail the Discount on this Report @https://www.bigmarketresearch.com/request-for-discount/3848332?utm_source=SHASHI&utm_medium=MC

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Global Human Embryonic Stem Cells Market Definition and Scope

Chapter 3. Global Human Embryonic Stem Cells Market Dynamics

Chapter 4. Global Human Embryonic Stem Cells Market: Industry Analysis

Chapter 5. Global Human Embryonic Stem Cells Market, by Method

Chapter 6. Global Human Embryonic Stem Cells Market, by Style

Chapter 7. Global Human Embryonic Stem Cells Market, by Application

Chapter 8. Global Human Embryonic Stem Cells Market, Regional Analysis

Chapter 9. Competitive Intelligence

Chapter 10. Research Process

Tending Report :

Hydraulic Cylinder Market: Key Players, Growth, Analysis, 2019-2026

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers in one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact Us:

Mr. Abhishek Paliwal

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Call answer Direct:+1-971-202-1575

Call answer Toll-Free:+1-800-910-6452

Emailhelp@bigmarketresearch.com

Go here to read the rest:
Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc - The...

4D hires a trio of area heads as it ramps up its gene therapy pipeline – FierceBiotech

4D Molecular Therapeutics raised $75 million in June to get several gene therapy programs into and through the clinic. Now, its adding a trio of executives to spearhead its work in heart, eye and lung diseases as it looks to shepherd treatments in those focus areas forward.

Robert Fishman, M.D. becomes 4Ds chief medical officer and therapeutic area head for pulmonology. He joins from Xoc Pharmaceuticals, where as chief medical officer he led phase 1 development for programs in Parkinsons disease and migraine. Before that, he headed clinical development at InterMune, overseeing the pivotal trial of Esbriet, an idiopathic pulmonary fibrosis drug now marketed by Roche.

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

RELATED: Restoring eyesight with genetically engineered stem cells

Raphael Schiffmann, M.D., signs on as senior vice president and therapeutic area head for 4Ds cardiology stable. He was previously director of the Institute of Metabolic Disease at the Baylor Research Institute and the lead investigator of the developmental and metabolic neurology branch at the NIHs National Institute of Neurological Disorders and Stroke.

Robert Kim, M.D., joins 4D as a senior vice president and clinical therapeutic area head of ophthalmology. Hes held multiple chief medical officer roles at ViewPoint Therapeutics, Apellis Pharma and Vision Medicines, and earlier in his career worked in ophthalmology at GlaxoSmithKline, Genentech and Novartis.

The three executives arrive six months after 4D topped up its coffers with a $75 million series C round. The capital, which came two years after a $90 million B round, was earmarked to push three programs into the clinic, including two that are partnered with Roche.

Those programs include 4D-310, a treatment for Fabry disease in which patients cells accumulate a type of fat called globotriaosylceramide, and 4D-125, a treatment for the eye disease X-linked retinitis pigmentosa. Roche has the exclusive right to develop and commercialize the latter. Roche has licensed the third prospect, 4D-110, a treatment for a type of vision loss called choroideremia.

RELATED: 4D raises $90M to move gene therapies into clinical testing with AstraZeneca and Roche

The funds will also bankroll the development of 4Ds preclinical pipeline, including IND-enabling studies for 4D-710, a program in cystic fibrosis, and other candidates for neuromuscular diseases and ophthalmology.

With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas," said 4D CEO David Kim, M.D., in a statement.

Read the original here:
4D hires a trio of area heads as it ramps up its gene therapy pipeline - FierceBiotech

Nobel Prize history from the year you were born – Herald & Review

Nobel Prize history from the year you were born

Since 1901, Nobel Prizes have honored the worlds best and brightest and showcased the work of brilliant and creative minds, thanks to Swedish businessman Alfred Nobel, who made his fortune with the invention of dynamite.

The Prize in Physiology or Medicine often honors those whose discoveries led to medical breakthroughs, new drug treatments, or a better understanding of the human body that benefit us all.

The Prize in Literature celebrates those skilled in telling stories, creating poetry, and translating the human experience into words. The Prizes in Chemistry and Physics remind most of us how little we understand of genetics, atomic structures, or the universe around us, celebrating the scientists who further knowledge. A later addition to the award roster, the Nobel Memorial Prize in Economic Sciences is not an original Prize, but was established by the Central Bank of Sweden in 1968 as a memorial to Alfred Nobel. It applauds those who can unravel the mysteries of markets, trade, and money.

The Peace Prize celebrates, in Nobels words, the person who shall have done the most or the best work for fraternity between nations, the abolition or reduction of standing armies and for the holding and promotion of peace congresses, sometimes risking their lives to do so.

So precious are the awards that the medals of German physicists Max von Laue and James Franck, stored away for safekeeping in Copenhagen during World War II, were dissolved in acid to keep them away from approaching Nazi troops. After the war, the gold was reconstituted from the acid and recast into new medals.

But Nobel history has not been entirely noble. In 1939, British Prime Minister Neville Chamberlain, known for his policy of appeasement toward Nazi Germany, was nominated for the Peace Prize. In an act of irony and protest, members of the Swedish Parliament nominated Adolf Hitler. That nomination was withdrawn. Some recipients have ordered oppressive crackdowns on their own people or ignored genocides, either before or after receiving the Prize. The 1918 Nobel Prize in Chemistry was given to Germanys Fritz Haber, who invented a method of producing ammonia on a large scale, which was helpful in making fertilizer. But the same chemist helped develop the chlorine gas that was used as a chemical weapon in World War I.

Stacker looked at facts and events related to the Nobel Prizes each year from 1931 to 2020, drawing from the Nobel Committees recollections and announcements, news stories, and historical accounts.

Take a look, and see what was happening with the Nobel Prizes the year you were born.

You may also like: 100 years of military history

Erik Axel Karlfeldt was the first Nobel winner to be awarded posthumously. The Swedish poet was alive during the nomination and deliberation process but died six months before the Literature Prize was announced. As of 1974, the rules were changed so that awards can only be given posthumously if the winner dies after the announcement but before the formal award is bestowed.

John Galsworthy, author of The Forsyte Saga, was awarded the Nobel Prize in Literature. The chronicle of English life became a hugely popular miniseries in 1967 on American public television.

Ivan Bunin, the first Russian writer to win the Nobel Prize in Literature, departed Russia after the 1917 revolution and settled in France as a permanent exile. His books were banned by Soviet authorities due to his anti-Bolshevik writing. To accept his Nobel Prize in Stockholm, Bunin had to travel through Germany, where he was arrested by the Nazis and falsely accused of smuggling jewels. The Nazis forced him to drink a bottle of castor oil before letting him go.

Three Americans shared the Nobel Prize in Physiology or Medicine for their research into anemia, when the bodys red blood cell count is low. George Whipple found dogs formed new blood cells by eating diets of liver, kidney, meat, and apricots, and George Minot and William Murphy applied those findings to humans with pernicious anemia. They also delved into the cause of pernicious anemia: a shortage of vitamin B12.

The 1935 Peace Prize was awarded to Carl von Ossietzky, a journalist and critic of Nazi Germany who was being held in a concentration camp. Hitler would not allow him to accept the prize. He died in 1938 in a prison hospital. Also in 1935, married couple Frdric Joliot and Irne Joliot-Curie won the Nobel Prize in Chemistry. Joliot-Curie was the daughter of Marie Curie and Pierre Curie, also Nobel Prize winners.

The Norwegian royal family chose not to attend the Nobel ceremony following the controversial choice of German pacifist Carl von Ossietzky to win the Peace Prize. Critics said the prize decision would provoke Germany. The royal family offered no official explanation for skipping the ceremony, but it was widely believed that Norway wanted to distance itself from the prize selection.

American physicist Clinton Davisson won the Nobel Prize partly by accident. When he was testing the hypothetical relation between particle velocity and wavelength, he bombarded a nickel block with electrons and measured how they scattered. But when the nickel was baked at high heat after accidental contamination, the structure of its atoms changed, as did the patterns of the electrons, proving the hypothesis.

No Nobel prizes were awarded in 1940 due to World War II. Norway was occupied by German forces, and Adolf Hitler was angry about the 1936 Peace Prize awarded to Carl von Ossietzky, a journalist who disclosed that Germany had been secretly rearming, a violation of the Treaty of Versailles that ended World War I. Ossietzky was tried and convicted of treason.

You may also like: Counties with the highest rate of food-insecure children

Not only were no Nobel Prizes awarded while the world was locked in war, but a significant brain drain was underway that would see Europe lose many of its brilliant thinkers. By 1941, a dozen Nobel-winning scientists had left for England and the United States, including physicists Niels Bohr, a winner in 1922, Albert Einstein, who won in 1921, and Enrico Fermi, who won in 1938.

Ralph Bunche was principal secretary of the United Nations Palestine Commission when he was awarded the Peace Prize for his role in mediating the 1949 cease-fires between Israel and Arab states after the partition of Palestine. Bunche, an academic and U.S. State Department advisor, was the first Black person to receive a Nobel Prize.

You may also like: Former jobs of the governor of every state

The Nobel Memorial Prize in Economic Sciences was established in 1968 by Sveriges Riksbank, the central bank of Sweden. It was created to mark the banks 300th anniversary. The first recipients would be awarded in 1969.

The first Nobel Memorial Prize in Economic Sciences was shared by Norwegian economist Ragnar Frisch and Dutch economist Jan Tinbergen, who helped develop the study of economics based upon mathematics. Tinbergen created a model of macroeconomics, placing economic variables in mathematical relationships to each other. His younger brother, Nikolaas Tinbergen, was one of three scientists awarded the 1973 Nobel Prize in Physiology or Medicine for their studies of animal behavior, particularly how animals communicate and care for their young.

Swedens Ulf von Euler discovered the bodys neurotransmitter norepinephrine, which is involved in the fight-or-flight process, and was awarded the Nobel Prize in Physiology or Medicine. His father, Hans von Euler-Chelpin, won the Nobel Prize in Chemistry in 1929 for his research in the fermentation of sugar and the enzymes involved in the process.

You may also like: How Americans use the internet today, by the numbers

Physicist Dennis Gabor won the Nobel Prize in Physics for inventing the holograph, and German Chancellor Willy Brandt won the Peace Prize for helping ease relations between East and West Germany. Under his administration, West Germany signed a nuclear weapons non-proliferation treaty, reached a nonviolence deal with the Soviet Union, and laid the groundwork for making family visits easier in the divided city of Berlin.

In awarding the Prize in Literature, the Nobel Committee honored German writer Heinrich Bll, saying his a broad perspective on his time and a sensitive skill in characterization has contributed to a renewal of German literature." After World War II, Bll was part of the Gruppe 47, a number of influential writers who would meet over the course of three decades as they dealt with the wars destruction and the aftermath of the Holocaust.

In a controversial decision, the 1973 Nobel Peace Prize was awarded jointly to U.S. Secretary of State Henry Kissinger and Le Duc Tho of North Vietnam for the Vietnam ceasefire negotiations. But the North Vietnamese leader refused to accept the prize, on grounds that the war was ongoing and the United States violated terms of the agreement. Kissinger did not travel to Norway to accept the prize and said he wanted to return it but was told he could not do so.

Costa Rican President Oscar Arias Snchez is credited for his leadership in encouraging five presidents in Central America to sign a peace agreement ending the regions civil wars. The peace plan signed by Costa Rica, Guatemala, El Salvador, Honduras, and Nicaragua called for human rights safeguards, free elections, and an end to interference by other countries.

The winners of the Prize in Physiology or Medicine brought relief to millions with their drug discoveries. The work of Sir James Black led to the use of receptor-blocking drugs to treat heart disease, hypertension, and peptic ulcers, and collaborators Gertrude Elion and George Hitchings made discoveries that led to drugs for the treatment of leukemia, malaria, gout, and herpes virus infections.

Myanmars human rights activist Aung San Suu Kyi was under house arrest when she was awarded the Peace Prize. In 2015 she was released and elected to national office, but she has come under strong criticism for her countrys treatment of its Muslim Rohingya minority and its possible genocide. Calls were made for her Nobel Prize to be revoked, but the head of the Nobel Foundation said it would not be withdrawn for events that took place after it was awarded.

South Africa took the spotlight when the Nobel Peace Prize was awarded to Nelson Mandela and Frederik Willem de Klerk for their roles in ending the apartheid system of racial separation. Mandela was imprisoned 27 years for his political activism, and de Klerk, the president of South Africa, released him in 1990. They went on to work together to end apartheid and design a new constitution that allowed universal voting rights, regardless of race.

American John Nash was one of three winners of the Nobel Memorial Prize in Economic Sciences for his work on game theory. Nashs struggle with schizophrenia was portrayed in the 2001 Academy Award-winning film A Beautiful Mind, starring Russell Crowe as the Princeton-educated mathematician. His work, which became known as the Nash equilibrium, is used in understanding the processes of chance and decision-making.

Joseph Rotblat, a physicist and longtime opponent of nuclear weapon development, won the Nobel Peace Prize 50 years after atom bombs were dropped on Hiroshima and Nagasaki. He withdrew in 1943 from the Manhattan Project, which was producing nuclear weapons. He worked with the anti-nuclear Pugwash movement, a series of conferences with which he shared the Peace Prize.

You may also like: Most and least popular governors in America

Southeast Asias East Timor was highlighted when the Peace Prize was awarded to Carlos Belo and Jos Ramos-Horta. Ramos-Horta was a leader of resistance in East Timor to the occupation by Indonesia and helped build international support for self-determination, and Belo, a Roman Catholic bishop, demanded the United Nations and the United Nations Commission on Human Rights take notice. The Peace Prize is considered a major factor in East Timor achieving independence in 2002.

Citing the more than 100 million anti-personnel landmines estimated to be strewn around the world, the Nobel Committee gave the Peace Prize to the International Campaign to Ban Landmines and to its coordinator Jody Williams for their accomplishments in banning and clearing mines. Their work culminated in the United Nations Mine Ban Convention, adopted in 1997, that prohibited the stockpiling and use of landmines and required countries to clear mines.

Two political leadersDavid Trimble and John Humein Northern Ireland shared the Peace Prize for helping bring about the Good Friday Agreement that laid out plans for governance of Northern Ireland. Key to the agreement were the Protestant Ulster Unionist Party, led by Trimble, and the Catholic Social Democratic and Labour Party, led by Hume.

The Nobel Committee applauded Mdecins Sans Frontires, known as Doctors without Borders in English, for its extensive humanitarian work across several continents. It said the organization maintained a high degree of independence, helped build public opinion in opposition to humanitarian abuses, and helped forge contacts between sides in conflicts.

Understanding our relation to money earned the Nobel Prize for two American economists. James Heckman researched factors that affect statistical sampling, and his findings have been used to understand how early life experiences influence earnings potential and economic status. Daniel McFadden studied how people make decisions, developing so-called discrete choice models that can explain and predict behavior and are applied to such real-life uses as public transportation systems and senior housing.

You may also like: What the world's most polluted beaches look like today

Americans George Akerlof, Michael Spence, and Joseph Stiglitz were awarded the Nobel Memorial Prize in Economics for their work on markets with asymmetric informationmarkets in which one side has better information than the other. Akerlof looked at the consequences of such markets in areas like developing world lending and medical insurance, Spence demonstrated how market participants convey information, and Stiglitz showed how asymmetric markets work in areas like unemployment and credit.

Jimmy Carter was commended for decades of untiring effort to find peaceful solutions to international conflicts, to advance democracy and human rights, and to promote economic and social development. The Committee cited his foreign policy achievements including the Panama Canal treaties, Camp David Middle Eastern accord, and SALT II treaty with the Soviet Union as well as his founding afterward of The Carter Center, which specialized in international conflict mediation and election monitoring.

The creators of magnetic resonance imagining, or MRI, took home the Nobel Prize in Physiology or Medicine. Paul Lauterbur of the United States and Britains Sir Peter Mansfield researched the behavior of atoms and molecules in a magnetic field to develop interior imagery of the human body.

Wangari Maathai, the first female professor in Kenya, became the first African woman to win the Nobel Peace Prize. Already active in the nations democratic movement, Maathai launched a grassroots movement that mobilized women to plant trees to fight deforestation. Called the Green Belt Movement, it spread elsewhere in Africa and led to the planting of more than 30 million trees.

Winners of the Nobel Prize in Physiology or Medicine, Australians J. Robin Warren and Barry Marshall discovered the bacterium that causes gastritis and peptic ulcer disease. Their discovery ran counter to the commonly held belief that peptic ulcer disease was caused by lifestyle and stress. The revelation influenced research into the causes of other chronic inflammatory conditions and the links between chronic infection, inflammation, and cancer.

You may also like: Highest-paid employees in the White House

The winner of the Nobel Prize in Chemistry, American Roger Kornberg, researched the structure and role of an enzyme called RNA polymerase in a genetic process essential to building and maintaining molecular and cell structure. His father Arthur Kornberg won the 1959 Prize in Physiology or Medicine for his pioneering work in genetics.

Doris Lessing, author of dozens of books including the novel The Golden Notebook, became the oldest winner of the Nobel Prize in Literature at age 88. She told reporters from her doorstep in London that she was not that surprised because her name had been under consideration for decades. Either they were going to give it to me sometime before I popped off or not at all, she said.

The New York Times columnist Paul Krugman won the Nobel memorial Prize in Economic Sciences for his work in international trade patterns and economic geography. Krugman was instrumental in the development of New Trade Theory, which concerns factors in international market patterns such as economies of scale and the network effect, when goods become more valuable with wider use.

U.S. President Barack Obama was presented the Peace Prize during his first year in office. The Committee said it recognized Obama for his "extraordinary efforts to strengthen international diplomacy and cooperation between peoples. Critics questioned whether Obama, the countrys first Black president, had earned such a distinction so early in his term.

Chinas Liu Xiaobo was in prison when he was awarded the Nobel Peace Prize. The human rights activist had been jailed following the 1989 massacre at Tiananmen Square, imprisoned again for criticizing Chinese policies toward Taiwan and the Dalai Lama, and sentenced to prison again in 2009 for seeking political reform. He died in 2017.

You may also like: The original Woodstock, by the numbers

When the Nobel Prize in Physiology or Medicine was announced, the Foundation learned that one of the winners, Ralph Steinman, had died three days earlier of cancer. Although the rules say the awards are not given posthumously, it was decided that the Canadian immunologist should be a Nobel Laureate because the Nobel Assembly had announced the winners without knowing he was dead.

Sir John Gurdon of England and Shinya Yamanaka of Japan, winners of the Nobel Prize in Physiology or Medicine, researched the way cells and organisms develop. They discovered how mature specialized cells could be reprogrammed to become immature cells, a major medical breakthrough applicable to stem cell research.

The three American economists who shared the Nobel Prize made discoveries that help predict the long-term prices of stocks and bonds. Eugene Famas research was used in the development of stock index funds, Robert Shiller discovered certain dynamics about stock prices and dividends, and Lars Hansen looked at theories of risks and returns that are used in asset pricing.

At age 17, Malala Yousafzai was the youngest Nobel Laureate when she was awarded the 2014 Peace Prize. Yousafzai, an outspoken advocate for girls education and rights, survived an attempted assassination in 2012 by the Taliban in Pakistan. She shared the Peace Prize with Indian activist Kailash Satyarthi, who was honored for his work fighting child labor.

Jeffrey Hall, who shared the 2017 Nobel Prize in Physiology or Medicine for his work understanding the human body clock, had left science about a decade before winning his prize. He was outspoken about his frustration with what he saw as an inadequate, wasteful, and unfair research funding process.

At 96 years old, Arthur Ashkin became the oldest Nobel Laureate until he was surpassed by a 97-year-old winner the following year. Ashkin invented optical tweezers, sharp laser beams that can grab particles, atoms, molecules, and bacteria. The Nobel Prize in Literature was postponed due to scandal involving sexual misconduct, conflicts of interest, and financial malpractice at the Swedish Academy.

At 97, John Goodenough became the oldest Nobel Laureate when he won the Prize for Chemistry. His work led to the development of lithium-ion batteries, which had higher voltage than previous batteries, and are used to power mobile telephones and electric cars.

The three winners of the Prize in PhysicsBritains Roger Penrose, Germanys Reinhard Genzel, and Andrea Ghez of the United Stateswere honored for research into the existence and formation of black holes in the Milky Way. Penrose proved how the theory of relativity leads to the formation of black holes, while Genzel and Ghez discovered the role of a massive black hole at the center of the galaxy in affecting the orbits of stars.

You may also like: Iconic buildings that were demolished

Germanys Adolf Butenandt won the Nobel Prize in Chemistry for his research into sex hormones that would be used in the development of oral contraception. Like Richard Kuhn in 1938, he was forced by the Nazis to decline the prize but was able to accept the certificate and medal in 1949. Germanys Gerhard Domagk, whose research led to the development of antibiotics, also had to turn down the Nobel Prize in Physiology or Medicine but got it after the war.

While no Nobel Prizes were awarded, 1942 was the year that the name United Nations was coined by President Franklin Roosevelt in a declaration by 26 nations to stand together against the Axis powers. Founded three years later, the United Nations, along with its agencies, programs, and staff, has been awarded the Nobel Peace Prize a dozen times. The U.N.s High Commissioner for Refugees (UNHCR) has won it twice, and most recently, the U.N.s World Food Programme won in 2020.

Henrik Dam and Edward Doisy shared the Nobel Prize in Physiology or Medicine for their work in the discovery of vitamin K, which the human body uses for clotting and healing. Dam determined that Vitamin K is needed for blood to coagulate, and Doisy found ways to produce it artificially, which was useful in stopping bleeding in small children.

The Nobel Peace Prize was awarded to the International Committee of the Red Cross for the work it had done during the war on behalf of humanity. It was the first Peace Prize bestowed in five years; the prizes were not given out from 1939, the year Germany invaded Poland at the start of World War II, to 1943.

Two American activists shared the Nobel Peace Prize. One was Emily Greene Balch, co-founder of the Womens International League for Peace and Freedom and a professor at Wellesley College for 22 years until she was fired for her activism. John Raleigh Mott, head of the Young Mens Christian Association, promoted international youth programs, worked with relief programs for prisoners of war, and was an outspoken critic of colonial oppression and race discrimination.

Gerty Cori, the first woman to win the Nobel Prize in Physiology or Medicine, was honored with her husband Carl Cori for their work in understanding the metabolism process. When the couple moved to America in 1922 from Austria, Carl Cori was hired as a biochemist at a New York research institute. Gerty Cori could only find work as an assistant pathologist, despite having the same degrees and research experience, because she was a woman. She was finally allowed a position equal with her talent and experience at Washington University in St. Louis in 1938.

Although the Nobel Prize in Literature is considered to honor a writers body of work, the Nobel Academy singled out The Old Man and the Sea when it chose American author Ernest Hemingway. It said the novel demonstrated his mastery of the art of narrative.

The winner of the Chemistry Prize, Vincent du Vigneaud, studied biochemical sulphur compounds, including oxytocin, a hormone involved in sexual intimacy and reproduction. Sometimes called the cuddle or love hormone, it is released when people bond, including as couples or parents with children. Vigneaud isolated oxytocin, calculated its chemical composition, and determined how to produce it artificially.

You may also like: Countries that have mandatory voting

The king of Sweden goodnaturedly reprimanded John Bardeen for leaving most of his family homehis children were in schoolwhen he was awarded the Nobel Prize in Physics. The American physicist told the king he would bring his family the next time. Sure enough, Bardeen won a second Nobel Prize in 1972, and he took his whole family to theceremony.

Biochemists Severo Ochoa and Arthur Kornbergs work on DNA and RNA earned them the Nobel Prize in Physiology or Medicine. Ochoa discovered how to create RNA, and Kornberg, formerly a student of Ochoas, found ways of making DNA. Kornbergs son, Roger, a chemical physicist, also conducted genetic research and won the Nobel Prize in Chemistry in 2006.

Winners of the Nobel Prize in Physiology or Medicine, Roger Guillemin and Andrew Schally used pig brains and lamb brains in their research on hormonal roles and structure. They shared the prize with Rosalyn Yalow, a nuclear physicist who developed radioimmunoassay, a method that can measure extremely small amounts of bodily substances. It was used in helping determine the cause of type 2 diabetes.

In awarding the Peace Prize to the International Physicians for the Prevention of Nuclear War, the Nobel Committee singled out its Soviet founder Yevgeny Chazov and American founder Bernard Lown to accept the award because of their cooperative influence. The IPPNW consists of tens of thousands of medical professionals, now in 64 countries, who banded together in hopes of preventing and averting nuclear war.

You may also like: Oldest national parks in America

Indian leader Mahatma Gandhi was nominated five times for the Nobel Peace Prize, the final time being in 1948 not long before he was assassinated. That year, the Nobel Committee chose not to bestow any award, declaring there was no suitable living candidate.

The winner of the Nobel Prize in Medicine, Portugals Egas Moniz, invented the lobotomy. He discovered how a surgical incision into the brains prefrontal lobe could alter behavior. Lobotomies were used widely to treat mental illness in the 1940s and 1950s until they were widely recognized as dangerous, and medication for mental illness became more commonly prescribed.

The awarding of the Peace Prize to Dag Hammarskjld, the second Secretary-General of the United Nations, was only the second time a Nobel was given posthumously. The first occasion was the posthumous literature prize awarded to Erik Axel Karlfeldt in 1931. The rules were changed in 1974 so that prizes could not be awarded posthumously unless the winner dies after the announcement but before the award ceremony.

The winner of the Nobel Prize in Physiology or Medicine, to American James Watson, would later sell it at auction at Christies in 2014 to raise money for charity. Russian tycoon Alisher Usmanov paid $4.7 million, then said he was returning the award to the scientist. Watson won for discovering the structure of DNA along with Francis Crick.

Free-market economist Friedrich von Hayek, a critic of central planning, shared the Nobel Prize with Swedish economist Gunnar Myrdal. Hayek argued for a decentralized market system with open competition and disagreed with the use of government fiscal policy to moderate movements of the economy as promoted by economist John Maynard Keynes.

American economist Milton Friedman was awarded the Nobel Memorial Prize in Economic Sciences for his work on monetarypolicy. Friedman advocated for free markets and opposed government economic intervention. His views influenced the conservative fiscal policies of U.S. President Ronald Reagan and British Prime Minister Margaret Thatcher. He was a major proponent of school vouchersusing public tax funds to pay for students to attend private schoolsa system that remains hugely controversial to this day.

Mother Teresa of the Missionaries of Charity was given the Nobel Peace Prize for her work assisting the poor in Kolkata, especially its orphans, lepers, and terminally ill. Pope Francis declared the Albanian nun a saint in 2016. She started the Missionaries of Charity with a dozen nuns and it had nearly 5,000 at the time of her death in 1997.

Marking the 500th anniversary of Christopher Columbus landing in the Americas, Mayan Rigoberta Mench Tum of Guatemala was hailed for her campaign for human and Indigenousrights. Taking a global approach, she facilitated the use of international intermediaries in negotiations between guerrilla forces and the government, culminating in a 1996 peace agreement that ended a 36-year civil war.

Max Theiler of South Africa was honored for his research on yellow fever, a deadly disease found in subtropical and tropical South America and Africa and spread primarily by mosquitoes. Theiler discovered how to transmit the yellow fever virus to mice, helping produce weaker forms of the virus that could be used as a vaccine for humans.

For his role in the discovery of streptomycin, Selman Waksman was awarded the Nobel Prize in Physiology or Medicine. Streptomycin was the first antibiotic found to be effective against tuberculosis. Waksman studied how the bacteria that causes tuberculosis interacted with microorganisms in soil and found that a bacterium called Streptomyces griseus blocked its growth.

British Prime Minister Winston Churchill won the Nobel Prize in Literature for his works that included an autobiography, several volumes about the First and Second World Wars, and his notable speeches during World War II. From 1946 to 1953, Churchill was nominated in seven years for the Literature Prize and twice for the Nobel Peace Prize.

Ending conflict in the Middle East was the focus of Canadian historian and diplomat Lester Pearson, who won the Peace Prize for his role in ending violence that erupted in 1956 over control of the Suez Canal. The conflict among the major superpowers could have had severe global consequences. Thanks to Pearsons efforts, a United Nations Emergency Force was dispatched to oversee a cease-fire.

Russias Boris Pasternak was awarded the Nobel Prize in Literature, which he at first accepted but later was forced to turn down by Soviet authorities who banned his novel Doctor Zhivago. The only novel the poet wrote, Dr. Zhivago was deemed to be anti-Soviet and remained forbidden until the late 1980s.

Frances Jean-Paul Sartre was awarded, and declined, the Nobel Prize in Literature.He explained that he always declined official honors and that as a writer, he felt he should remain distinct from any institution.

The United Nations Childrens Fund, better known as UNICEF, was awarded the Nobel Peace Prize. UNICEF started out in 1946 providing food, clothes, and medicine to children and mothers but expanded to promote nutrition, school attendance, and health care in developing countries. The Nobel Committee honored UNICEF for its effort to enhance solidarity between nations and reduce the difference between rich and poor states.

You may also like: Most dangerous countries for journalists

Peyton Rous won the Nobel Prize in Physiology or Medicine when he was 87, the oldest winner ever in the category. The American studied the role of viruses in cancer cells and transmission. His work was based on research begun in the early 1910s.

Contributions to understanding how the human eye functions earned the Nobel Prize in Physiology or Medicine for a scientific trio. Finnish scientist Ragnar Granit researched the types of cones responsible for seeing color; American Keffer Hartline analyzed how the eye processes contrasts; and American George Wald studied the role of light in visual impressions.

Danish physicist Aage Bohr won the Nobel Prize for his experiments on the structure of atoms. His father, Niels Bohr, won the Nobel Prize in Physics in 1922, also for work on atomic structure. The elder Bohr created a theory that explained how moving electrons cause atoms to emit light.

You may also like: From Stonewall to today: 50 years of modern LGBTQ+ history

The Camp David Agreement, which laid out a framework for peace in the Middle East, earned the Nobel Peace Prize for Egyptian President Mohamed Anwar al-Sadat and Israeli Prime Minister Menachem Begin. U.S. President Jimmy Carter was to have been a third recipient, but a technicality prevented him from being nominated within the Committees deadline. But he won the Peace Prize nevertheless in 2002.

Alva Myrdal, along with Mexicican diplomat Alfonso Garca Robles, won the Nobel Peace Prize for working toward nuclear disarmament. Myrdal was a Swedish scientist, government official, and diplomat, and she was married to Gunnar Myrdal, a Swedish economist who was awarded an Economics Nobel in 1974.

Read the rest here:
Nobel Prize history from the year you were born - Herald & Review

Accumulated genetic variations: What they are and why they matter to a complete health picture – MedCity News

Genes are by no means a crystal ball, but they can be used to forecast susceptibility to a variety of conditions, from cancers and heart disease to chronic inflammatory conditions. As such, they can help healthcare professionals and patients make better care decisions.

Generally speaking, whenpeople today think about genetic predispositions, theythink about their parents and family trees.However, those inherited genetic variationsbequeathed by ourparents and grandparents are only a portion ofacomplete genetic picture and often not the most revealing one.Thegenetic variationsmost commonly linked to disease are actually?not?the ones from your parents; rather, they areacquiredas one ages.

Mom and Dad Cant Take All the Heat forAll Health Challenges Unlike inheritedgenetic predispositions,accumulatedgenetic changes(otherwise known as somatic)are the result ofenvironmental influences, such as smoking, chemicals or ultra-violet radiation. They can also stem from common errorscells make as they duplicate themselves over time.The expansion of these detrimental variations cause damage to DNA within blood cells,aphenomenon known as clonal hematopoiesis (CH), whichincreases susceptibility to many diseases, including many types of cancer.

Germline variations in genes still indicate potential vulnerabilities, with one in five healthy adults estimated to carry an inherited marker. However, these genetic abnormalities represent a static metric. Once individuals are tested for inherited variations, they will never need to do so again. Whats more, many of the predispositions that surfaced through this testing can be addressed through lifestyle and medical interventions. It boils down to being aware of them.

Somatic changes, on the other hand, can happen at any stage of life. While many of these changes have no clinical ramifications, some of them can exacerbate predispositions inherited from our parents because the disease is often the result of multiple genetic variations banding together, inherited or acquired.

The chances of an acquired variation accumulating and accelerating within the body increase significantly as we age, generally after the age of 40 and growing each decade. This could drastically change a patients health profile, casting inherited vulnerabilities into a new light without any warning or symptoms.

Understanding Accumulated VariationsA growing body of research links somatic changes to an increased likelihood of blood cancers and cardiovascular disease, both heart disease and stroke. The same research reveals that these accumulated genetic variations contribute to infection and severe inflammatory reactions, some of which are associated with severe cases of Covid-19.

A study conducted byJAMA Cardiologyexplores theconnectionbetween accumulated genetic change anda pro-inflammatory immune response that resembles the exaggerated cytokine release syndrome (CRS)experienced by patients with severeCovid-19.Notably,the researchfoundthat patients who experienced the most extreme inflammatory response carried variationsTET2 and DMNT3A, both of which accumulate in genes over time.

Another research report published inCancersanalyzingpatients hospitalized with severe Covid-19disease found a much higher frequency of clonal hematopoiesis (CH) of indeterminate potential (sometimes called clonal hematopoiesis of indeterminate potential or CHIP) ),an age-associated condition in cells,in all age groups.

Additionally,accumulatedDNA damage to the JAK2 gene has been found in alargeproportion of cancer-free patients with venous thrombosis, a known complicationof Covid-19.While preliminary,the findingsdemonstratecompellingcorrelations betweensomaticgenetic change andCovid-19 severity that could be used to identify patients prone to complications early, intervene soonerand inform treatment strategies.

It is believed thatproviders can applythese correlations to other areas of care toassess an individuals susceptibilityto a wide range of diseases, and ultimately improve and extend quality of life.

Improving Care Decisions with Somatic insights Augmenting currenthealth assessmentsand care strategies with accumulated geneticdatacan open new pathways for disease detection, response and prevention.The scientificand medicalcommunitieshaveonly scratched the surface ofwhat we can learn from these insights. Even so,understanding somatic damage showsgreatpromise for helping individualsstay ahead of their health concerns and respond in a more informed way.

Photo: Andy, Getty Images

Read more:
Accumulated genetic variations: What they are and why they matter to a complete health picture - MedCity News

Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price – Being Patient

Groundbreaking research in stem cells has propelled scientists understanding of neurodegenerative diseases, including Parksinsons. Could stem cell therapies one day help cure Alzheimers?

Clinical trials of stem cell therapies are now underway to repair the damaged cells of people with Parkinsons disease and age-related macular degeneration. Being Patient spoke with Jack Price, professor of developmental neurobiology at Kings College London and author of the book The Future of Brain Repair, about the potential and challenges of repairing the brain with stem cell therapy.

Being Patient: What is stem cell therapy?

Prof. Jack Price: Its the transplantation of stem cells, either directly into the brain or in a way that gives them access to the brain and influence the brain, to bring about a therapeutic effect.

Being Patient: Are there stem cells in the brain?

Prof. Jack Price: For many years, neuroscientists didnt think there were stem cells in the brain. We now know there are. We know about a population [of stem cells] thats become very important in our understanding of Alzheimers disease and in mood disorders like anxiety and depression. These are stem cells that are found in a part of the brain called the hippocampus.

But by and large, the brain doesnt have stem cells, unlike skin and other tissues in the body. The blood is the classic [example]: Theres a population of stem cells in the bone marrow that regenerates blood all the time.

Being Patient: What makes stem cells so special and why are they a focus of research?

Prof. Jack Price: The definition of stem cells is a population of cells that gives rise to other types of cells. In neural stem cells, precursor cells can make adult brain cells, nerve cells, glial cells, all the different cell types that make up the brain. If you have a disease like Alzheimers or any other neurodegenerative disease, where we know the key pathology is the loss of nerve cells, your brain doesnt normally have the ability to replace those lost brain cells. The idea was [that] if you put stem cells where the loss of brain cells has taken place, maybe those stem cells would replace the lost cells.

Being Patient: What is the potential of stem cell therapy in treating neurodegenerative diseases?

Prof. Jack Price: Theres a piece of absolutely brilliant stem cell science that was done by Shinya Yamanaka in Kyoto in 2006. He showed you could effectively take any cell through a very straightforward genetic manipulation that he discovered, [and] turn them into what we call pluripotent stem cells, which are cells that can make any cell type in the body. They also have an ability that other stem cells generally dont: They can build tissue. If you grow them in a little culture dish, they can start to make little pieces of brain called organoids or cerebroids. This was a groundbreaking technology.

In Parkinsons disease, theres enormous progress and clinical trials are underway now. We know more about the pathology of Parkinsons disease [than in Alzheimers]. The pathology of Alzheimers turns out to be quite complex, and weve had, over the years, quite a few ideas about how it worked. But [turning] those into actual therapies hasnt quite worked as we expected, and we keep having to go back and rethink whats going on in Alzheimers.

The pathology of Parkinsons disease is also difficult. Its not trivial. But at the same time, one thing is clear: a lot of the pathology is associated with the loss of a particular population of nerve cells the midbrain dopaminergic cells. We can start with these pluripotent stem cells and make them make precisely the right type of dopaminergic cell that we know is lost in Parkinsons disease.

This is built on 30 [to] 40 years of research of people trying to find exactly the right cell type to work [with] in Parkinsons disease. They had some early success and fell backwards. But this technology looks much more precise than everything anybodys ever tried before.

In age-related macular degeneration, the disease of the eye where you lose your retinal photoreceptors, there are very clever strategies now where people are using these pluripotent stem cells to make a thing called a retinal pigment epithelium. It lies behind the retina, but its what supports the photoreceptors. It turns out, thats what goes wrong in age-related macular degeneration.

Being Patient: Are there any stem cell therapy approved to treat brain disorders?

Prof. Jack Price: There are no licensed stem cell therapy for any brain disorders anywhere in the world for the simple reason [that] nobody has shown one works. There are a lot of stem cell clinics in the U.S. and somewhat fewer elsewhere who are offering cell therapies that are untested. Theyll put stem cells into you for any disorder youve got. Those cell therapies do not work.

A lot of genuine companies are trying to get these cell therapies to work in clinical trials and falling flat on their face quite often, despite their best efforts. 90% of clinical trials fail, and thats clinical trials of conventional drugs by drug companies that know what theyre doing.

What do you suppose is the chance with a stem cell therapy [that] we dont really understand how it works, [that] we dont quite know how to manufacture it properly, [and that] we dont quite know what cells we really want, of working? The chance is almost zero. These companies know that, which is why theyre not going to clinical trials.

The interview has been edited for length and clarity.

Contact Nicholas Chan at nicholas@beingpatient.com

Link:
Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient